How Does CAR-T Therapy’s Efficacy Translate to Clinical Value for Hong Kong Patients with Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap? (H. T. Wong , Trans.). (2026). Journal of Medicine and Life Sciences, 2(1), 53-70. https://doi.org/10.71222/dt007s28